Construction and Expression of Mouse-human Chimeric Antibody SZ-51 Specific for Activated Platelet P-selectin

Summary

A murine monoclonal (mAb) SZ-51 specific for human P-selectin may be used for in vivo thrombus imaging and for the targeting of fibrinolytic agents to thrombi. In order to reduce the immunogenicity of the murine mAb SZ-51 in humans, we cloned and sequenced the cDNAs encoding the variable region of mAb SZ-51 in order to develop mouse/human chimeric reagents. The E. coli expression vector. pHENl-SZ51 Fab/Hu was constructed by fusing the variable regions of mAb SZ-51 with human IgG γICHI and Cκ genes. The constructs were introduced into E. coli HB2151 for expression of soluble chimeric Fab fragment. We also constructed two fusion products by joining the variable regions of mouse antibody to the appropriate constant regions of human Igγl and κ. These chimeras were cloned into two eukaryotic selectable expression vectors separately, which were then cotransfected into a non-Ig secreting murine myeloma line SP2/0 with lipofectin reagent. Six cell lines remained positive for Ig secretion. The highest producing cell line, which showed stable integration and expression at 5 mg/1 of culture, was selected for the large scale production of chimeric antibody. Immunoblotting analysis demonstrated that both of the chimeric antibodies (SZ51Fab/Hu, SZ51/Hu) in the culture supernatants, like the native mAb SZ-51, bind P-selectin. In addition, the whole chimeric antibody can compete for binding to activated platelets with murine SZ-51. Therefore, the SZ-51 chimeric antibody may be a potential agent for diagnosis and treatment of thrombotic diseases in the future.

• References

• 1 Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379-387
• 2 McEver RP. In: Structure, Function, and Regulation of Molecules Involved in Leukocyte Adhesion. Lipsky PE, Rothlein R, Kishimoto TK, Faanes RB. Smith CW. (eds). New York: Springer: 1993. pp 135-150
• 3 Palabrica TM, Furie BC, Konstam MA, Aronovitz MJ, Connolly R, Brockway BA, Ramberg KL, Furie B. Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. Proc Natl AcadSci USA 1989; 86: 1036-1040
• 4 Kurome T, Katayama M, Muradami K, Hashino K, Kamihagi K, Yasumoto M, Kato I. Expression of recombinant mouse/human chimeric antibody specific to human GMP-140/P-selectin. J Biochem (Tokyo) 1994; 115: 608-614
• 5 Wu GX, Xi XD, Li PX, Chu XH, Ruan CG. Preparation of a monoclonal antibody, SZ-51, that recognizes an a-granule membrane protein (GM-140) on the surface of activated platelets. Nour Rev Fr Hematol 1990; 32: 231-235
• 6 Wu JE, He GR, Wu GX, Ruan CG. Radioimmunoimaging of experimental arterial and venous thrombi in dogs with^99mTc-labeled monoclonal antiactivated platelet antibody SZ-51. Nucl Med Commun 1993; 14: 1088-1092
• 7 Du L, Yu RR, Hua ZC, Zhu DX, Wu GX, Ruan CG. Fibrinolytic effect of a chemical conjugate composed of anti-activated human platelets monoclonal antibody and urokinase. Science in China (series B) 1993; 23: 32-37
• 8 Levy RL, Miller RA. Biological and clinical implications of lymphocyte hybrid-omas: tumor therapy with monoclonal antibodies. Ann Rev Med 1983; 34: 107-122
• 9 Rodwell JD. Engineering monoclonal antibodies. Nature 1989; 342: 99-100
• 10 Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-299
• 11 Sefafini AN. From monoclonal antibodies to peptides and molecular recognition units: an overview. J Nucl Med 1993; 34: 533-535
• 12 Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-6855
• 13 Bulens F, Vandamme A-M, Bernar H, Nelles L, Lijnen RH, Collen D. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer. Eur J Biochem 1991; 195: 235-242
• 14 Jones PT, Dear PH, Foote J, Neuberg MS, Winter G. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-525
• 15 Riechamann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327
• 16 Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen binding proteins. Science 1988; 242: 423-426
• 17 Better M, Chanf CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment. Science 1988; 240: 1041-1043
• 18 Laroche Y, Demaeyer M, Stassen J-M, Gansemans Y, Demarsin E, Matthyssens G, Collen D, Holvoet P. Characterization of a recombinant singlechain molecular comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. J Biol Chem 1991; 266: 16343-16349
• 19 Ruan CG, Du XP, Xi XD, Castaldi PA, Berndt MC, murin A. antiglycoprotein lb complex monoclonal antibody. SZ-2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood 1987; 69: 570-577
• 20 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989
• 21 Gu JM, Xu WF, Wang XD, Wu QY, Chi CW, Ruan CG. Identification of a nonsense mutation at amino acid 584-arginine of platelet glycoprotein lib in patients with type I Glanzmann thrombasthenia. Br J Haemotol 1993; 83: 442-449
• 22 Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991; 19: 41337-41340
• 23 Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224: 487-499
• 24 Koppel GA. Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconjugate Chem 1990; 01: 13-16
• 25 Bode C, Matsueda GR, Hui KY, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985; 229: 765-769
• 26 Oster ZH, Srivastava SC, Som P, Meinken GE, Scudder LE, Yamamoto K, Atkins HL, Brill AB, Coller BS. Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody. Proc Natl Acad Sci USA 1985; 82: 3465-3468
• 27 Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immunores-ponse to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-1535
• 28 Liu AY, Robinson RR, Hellstrom KE, Murray Jr ED, Chang CP, Hellstrom I. Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987; 84: 3439-3443
• 29 Boulianne GL, Williams GT, Fox RO. Recombinant antibodies possessing novel effect functions. Nature 1984; 312: 604-608
• 30 Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 02: 1394-1399
• 31 LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220-4224
• 32 Knight DM, Wagner C, Jordan R, McAleer MF, De Rita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-1281